The Mayo Clinic, through the vehicle of the North Central Cancer Treatment Group (NCCTG) and, increasingly, through the Alliance for Clinical Trials in Oncology (aka, Alliance or ACTION), will serve as a primary research base for the 34 CCOPs with current NCCTG affiliations, providing both treatment and cancer control trials. We will also serve as a research base for cancer control and treatment protocol activity of non-CCOP members of the NCCTG. We will cooperate with our affiliated CCOPs and other members in conducting appropriate continuing education and workshops. The research base will provide training and active support for their data managers/research associates and oncology nurses. We will coordinate their multidisciplinary involvement in clinical cancer research protocols. By group meetings involving NCCTG and Alliance members, we will facilitate the review of ongoing research, plan future research and conduct related professional activities. The research bases will continue the rigid quality control procedures which have proved so successful in the past, and upgrade these procedures as indicated. We will constantly monitor CCOP and member performance, not only by timely review of patient accrual, data sheets, pathology material, operative reports, and radiation therapy port films, but also by periodic, randomly-scheduled monitoring site visits. The research bases will work with investigators and members in preparing publications as well as presentations for national and regional meetings. We will make every effort to provide members with reasons to be proud of their participation in the National Cancer Program. Our focus, over this grant period, will be on the further expansion of our cancer control efforts to include high priority symptoms adversely affecting completion of cancer treatment as well as survivorship quality, cancer prevention, and screening. We will incorporate associated basic laboratory support, leading to scientifically rigorous translational research efforts. Lastly, we will strive to meld ourselves, with two other current cooperative oncology groups (CALGB and ACOSOG) to become one Alliance group to continue the efforts described in this current grant proposal.
This project is very relevant to public health as cancer is such a large clinical problem leading to substantial disability and death. This program will define optimal means for controlling symptoms related to cancer and/or cancer therapy along with investigating methods to detect cancer early and prevent cancer. It will involve academic medical centers and also non-academic cancer clinical practice sites.
|Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650|
|Foster, Jared C; Le-Rademacher, Jennifer G; Feliciano, Josephine L et al. (2017) Comparative ""nocebo effects"" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort. Cancer 123:4193-4198|
|Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58|
|Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703|
|Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662|
|Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85|
|Kottschade, Lisa; Novotny, Paul; Lyss, Alan et al. (2016) Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer 24:2661-7|
|Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55|
|Atherton, Pamela J; Burger, Kelli N; Pederson, Levi D et al. (2016) Patient-reported outcomes questionnaire compliance in Cancer Cooperative Group Trials (Alliance N0992). Clin Trials 13:612-620|
|Miller, Robert C; Petereit, Daniel G; Sloan, Jeff A et al. (2016) N08C9 (Alliance): A Phase 3 Randomized Study of Sulfasalazine Versus Placebo in the Prevention of Acute Diarrhea in Patients Receiving Pelvic Radiation Therapy. Int J Radiat Oncol Biol Phys 95:1168-74|
Showing the most recent 10 out of 377 publications